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Background: Little has been known about the immunological milieu of the 
skin-draining lymph nodes (LNs) in mycosis fungoides (MF). Objectives: We 
studied dendritic cell (DC) subsets in the dermatopathic lymphadenitis of MF 
patients. Methods: We immunohistochemically examined DC subsets and their 
distribution in 16 LN samples from 14 patients with MF (N1 LN, eight patients; 
N2, four; and N3, four), and we compared them with non-metastatic sentinel LNs 
from eight patients with melanoma. Results: The number of S-100 protein+ DCs 
was markedly increased in the LNs from the MF patients, and the major 
component was DC-LAMP+ mature DCs in the outer and paracortex areas, 
where DC-SIGN+ immature DCs were relatively decreased in proportion. In 
contrast, DC-SIGN+ cells were relatively increased in proportion compared to 
DC-LAMP+ cells in the medulla. Although no significant difference was observed 
in the proportions of CD1a+ or Langerin+ DCs among the N1, N2, and N3 nodes, 
CD163+ M2-type macrophages were increased in number in the N2 and N3 
nodes. Conclusions: Our observations indicate that mature DCs were 
accumulated in the outer and paracortex areas in dermatopathic lymphadenitis, 
and M2-type macrophages might increase in number during disease 
progression. 
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Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma 
(CTCL), characterized by the epidermotropic infiltration of clonal CD4-positive 
T-lymphocytes. Typically, the clinical course of MF is indolent with a slow 
progression from patches to plaques, and occasionally to tumors. MF lesions 
start and progress predominantly in the skin and eventually to lymph nodes 
(LNs) and/or peripheral blood [1, 2]. In 2007, a revised version of the MF/Sézary 
syndrome (SS) staging system was proposed through several consensus 
meetings, based on the histopathological, phenotypic and molecular 
characteristics of MF/SS [3], and the system was further revised in 2011 [4]. 
The LN involvement in MF/SS has been classified into four categories: N0, N1, 
N2 and N3. The N1 and N2 categories correspond to the previous designation 
“dermatopathic lymphadenitis” with the minimal involvement of neoplastic T cells. 
Partially or completely effaced LNs in MF/SS, designated N3, uniformly show a 
clonal rearrangement of T-cell receptor (TCR). A key aspect of the N 
classification depends on the histopathological findings, including the degree of 
infiltrating malignant cells into LNs and the nodal architecture. 
The recent elucidation of the immunological background of MF/SS has provided 
a more comprehensive view of the immunological milieu, especially in the skin 
and peripheral blood. Although the role of dendritic cells (DCs) in CTCL has 
been gradually clarified [2, 5, 6], little has been known about DC subsets and 
their properties in the node involvement. In the present study, to clarify the 
immunological milieu of the skin-draining LNs in CTCL, we examined DC 
phenotypes and their distribution in LNs from patients with MF (16 samples from 
14 patients), and compared them with those of non-metastatic sentinel LNs from 
eight patients with melanoma (pT1–pT4b). 
 
Materials and methods 
 
Patients and materials 
Sixteen inguinal LN samples from 14 patients with MF were used for the present 
study (table 1). All patients were fully assessed by clinicopathological findings, 
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radiological examination and laboratory data according to the TNM classification 
for MF/SS [3, 4]. The diagnoses were stage IIA in six patients, IIB in two, IIIA in 
two, and IVA2 in four. Eight of the 16 LNs were an N1 node, four were an N2 
node, and four were an N3 node. 
Eight non-metastatic sentinel LNs from eight patients with melanoma (tumor 
stage pT1a, two patients; pT2b, two; pT3b, one; pT4a, two; pT4b, one), were 
used as a control group. Five LNs were obtained from the inguinal area, two LNs 
were from cervical area and one was from axillae. Although these LNs did not 
show any histopathologic changes suggestive of dermatopathic lymphadenitis, 
we could not exclude the possibility of some alterations in the cellular 
components because of the draining LNs of the melanoma patients. 
The present study was approved by the Institutional Review Board of Okayama 
University Hospital (No. 952), and all patients provided written informed consent 
to have their skin biopsy or LN resection used, in accord with the 1975 
Declaration of Helsinki. 
 
Immunohistochemistry 
All biopsy specimens from the resected LNs were fixed in 10% formalin and 
embedded in paraffin in a routine manner. Tissue sections were cut and then 
stained with hematoxylin and eosin. Immunohistochemical staining was 
performed with antibodies to CD3, CD4, CD8, CD20, CD79a, S-100 protein, 
CD1a, CD14, CD68, DC-LAMP (CD208), DC-SIGN (CD209), Langerin (CD207), 
and CD163. Antibodies were purchased from Nichireibio (CD3, CD20, CD79a), 
Becton Dickinson (CD4, CD8), Dako (S-100 protein, CD68), Immunotech (CD1a, 
DC-LAMP), Novocastra (Langerin, CD14), Abcam (DC-SIGN), and Biorbyt 
(CD163). 
The absence of metastasis in the sentinel LN samples from the melanoma 
patients was confirmed by two methods: immunohistochemistry with antibodies 
to S-100 protein (Dako), HMB-45 (Signet), Tyrosinase (Novocastra) and MART-1 
(Dako) and reverse transcriptase-polymerase chain reaction (RT-PCR) using 
primer sets specific for gp100, melan A, and tyrosinase. 
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Formalin-fixed, paraffin-embedded specimens were deparaffinized with xylol, 
and antigen retrieval was performed with S1699 solution (Dako) in a water bath 
at 96°C for 40 min. The sections were incubated with first antibodies at room 
temperature for 60 min, and further reacted by the avidin-biotin complex/alkaline 
phosphatase method (E0678: Dako Cytomation, Glostrup, Denmark). 
 
Double immunofluorescence staining 
Tissue sections were first incubated with rabbit anti-human S-100 protein 
antibody, then incubated with mouse monoclonal anti-human CD1a, 
CD207/Langerin, CD208/DC-LAMP, CD209/DC-SIGN, CD68, or CD14 at room 
temperature for 60 min. The sections were further reacted with fluorescence 
isothiocyanate (FITC)-conjugated donkey anti-rabbit IgG (Green) and 
Cy3-conjugated donkey anti-mouse IgG (Red) at 4°C overnight. 
 
Digital images 
Digital images were obtained using a photo-imaging system (V-100, Olympus, 
Tokyo). The numbers of the antibody-positive cells were enumerated in three 
randomly selected fields (original magnification; ×400) per section, and the 
results are expressed as the mean ± standard deviation (SD)/mm2. The 
proportion of antibody-positive cells is expressed as the percentage of the 




The comparisons between the MF and control groups were performed using 







DC subsets in dermatopathic lymphadenitis 
Compared with the non-metastatic sentinel LNs from melanoma patients, 
dermatopathic lymphadenitis, including the N1 and N2 of MF patients, revealed 
the accumulation of S-100 protein+ T-zone histiocytes in the outer and 
paracortex areas (642.5 ± 133.4 vs. 201.3 ± 94.5, p=0.0002) (figure 1). The N2 
LNs showed maximal S-100 protein+ cell infiltration, whereas the N3 nodes 
contained a decreased number of S-100 protein+ cells because of the massive 
infiltration of neoplastic cells (N1 vs. N2: 580.0 ± 85.2 vs. 767.5 ± 130.5, p=0.027; 
N2 vs. N3: 767.5 ± 130.5 vs. 253.3 ± 118.4, p=0.0095). The numbers of other DC 
subsets in the N1 and N2 LNs were as follows: mean number of DC-LAMP+ 
cells, 508.3 ± 121.0; CD1a+ cells, 211.7 ± 104.2; DC-SIGN+ cells, 95.8 ± 76.6; 
Langerin+ cells, 85.0 ± 33.7. 
In the N1 and N2 LNs, various types of DC subsets and other non-lymphoid cell 
types were detected by the double immunofluorescence study. The vast majority 
of S-100 protein+ cells co-expressed DC-specific antigens including CD1a, 
Langerin (CD207), DC-SIGN (CD209) and DC-LAMP (CD208) (figure 2). Most of 
the S-100 protein+ cells were negative for CD68 and CD14, although the exact 
discrimination of the co-expression was limited in the tissue sections. 
 
Localization of DC subsets in the LNs 
S-100 protein+ cells were distributed, at various densities, throughout the entire 
cortex, lymph follicles, and medulla in the LNs obtained from the patients with 
MF or melanoma. We focused on the DC subsets infiltrating in the outer cortex, 
paracortex and medulla, excluding S-100 protein+ follicular dendritic cells. 
Compared to the non-metastatic LNs from melanoma patients, DC-LAMP 
(CD208)+ cells were significantly increased in density in the outer and 
paracortex areas (T-cell zone) of the N1 and N2 LNs from MF patients, where a 
small number of DC-SIGN (CD209)+ cells were present (figure 3). No difference 
was observed in the localization of Langerin (CD207)+ or CD1a+ cells; these cell 
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types were present in the outer and paracortex areas and the medulla. These 
observations indicated that mature DC-LAMP (CD208)+ cells were a major 
component of S-100 protein+ DCs in the outer and paracortex areas. 
 
Proportion of DC subsets to S-100 protein+ cells in the N1, N2 and N3 
nodes 
Many S-100 protein+ cells, designated as “T-zone histiocytes” were found in the 
outer and paracortex areas of the N1 and N2 LNs. The proportion of 
DC-LAMP(CD208)+ cells to all S-100 protein+ cells was significantly increased 
in the outer and paracortex areas of MF compared to those in the non-metastatic 
LNs of melanoma (median proportion: N1 LNs, 77.0% vs. 39.5%, p=0.0009; N2 
LNs, 85.5% vs. 39.5%, p=0.0084, respectively) (figure 4). No difference was 
observed in the density of DC-LAMP (CD208)+ cells between the N1 and N2 
LNs (median 80.5% vs. 87.0%, p=0.5515, respectively).  
The proportion of DC-SIGN+ cells was significantly decreased in the 
dermatopathic lymphadenitis of MF (N1+N2) compared to that of the control 
group (14.5% vs. 36.6%, p=0.0481, respectively), although there was no 
significant difference between the N1 and N2 LNs. No significant difference was 
observed in the proportion in the N1 (14.5%, p=0.1008) or N2 LNs (11.0%, 
p=0.1054), as compared with those in control (median proportion: 36.5%). 
No significant difference was observed in the proportion of CD1a+ or Langerin 
(CD207)+ cells to S-100 protein+ cells between the N1 and N2 LNs (CD1a+: 
34.0% vs. 42.0%, p=0.5697; Langerin+; 13.5% vs. 16.0%, p=0.6085, 
respectively), or between the MF (N1+N2) and melanoma groups (CD1a+: 
34.5% vs. 40%, p=0.938; Langerin (CD207)+: 13.5% and 13.5%, p=0.969, 
respectively) (figure 5). 
 
Increase of CD163+ M2-type macrophages in the N2 nodes 
CD163+ M2-type macrophages were absent or at the background level in the 
early stage of dermatopathic lymphadenitis in the N1 LNs, but the number of 
CD163+ cells was increased in the N2 and N3 nodes (figure 6). The mean 
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numbers of CD163+ cells in the N2 and N3 nodes were 4.8 ± 2.6 





Dermatopathic lymphadenitis is a reactive lymphoid hyperplasia that commonly 
involves regional LNs in patients with MF [7, 8]. The histopathologic hallmark is a 
marked expansion of the paracortex areas because of the infiltration of 
pale-staining cells, designated as T-zone histiocytes, representing both 
interdigitating reticulum cells and Langerhans cells [9, 10]. S-100 protein is a 
characteristic marker for DCs in LNs, but we could not exclude a small number 
of non-DCs positive for S-100 protein such as benign nevocytes, sinus 
histiocytes, and Schwann cells. Our present findings demonstrated that a variety 
of DC subsets were accumulated in the outer cortex, paracortex, and medulla in 
the N1 and N2 LNs, where DC-LAMP+ DCs were a major subset, followed by 
CD1a+, DC-SIGN+, and Langerin (CD207)+ DCs. 
DC-LAMP (CD208) is a molecule specifically expressed by mature DCs, and 
DC-SIGN (CD209) is known to be expressed by immature DCs, which are 
capable of inducing immunological tolerance [5]. Although we observed S-100 
protein+ cells throughout the LNs in the present study, the localization of DC 
subsets was characteristic: mature DC-LAMP (CD208)+ cells were observed 
mainly in the outer and paracortex areas and conversely decreased in number in 
the medulla. In contrast, immature DC-SIGN (CD209)+ cells were observed 
predominantly in the medulla. 
It was reported that the presence of mature DC-LAMP (CD208)+ cells and 
activated T-cells was associated with the longer survival of patients with 
melanoma and that these cells could be a marker of a functional immune 
response against melanoma progression, then the high density of DC-LAMP 
(CD208)+ cells in melanoma draining sentinel LNs is associated with significant 
and prolonged overall survival benefit, reinforcing the notion that the immune 
system plays an active role in limiting the spread of melanoma [11, 12]. In 
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addition, a dynamic change of DC subsets was reported, in which mature DC 
subsets such as CD83+ and DC-LAMP (CD208)+ cells were decreased in 
number prior to the metastatic invasion of breast carcinoma cells to the LNs; 
once the metastasis was established however, mature DCs were increased in 
number, associated with the Th1-skewed immune responses [13]. As discussed 
in melanoma, we speculate that the increase of mature DC-LAMP (CD208)+ 
DCs with a concomitant decrease of DC-SIGN (CD209)+ DCs might be induced 
by the invasion of neoplastic MF cells to the LNs, and may contribute to the 
protection of tumor growth. 
Although we observed no clear difference in the DC subset proportion between 
the N1 and N2 LNs, the numbers of CD163+ M2-type macrophages were 
different: they were absent or at a background level in the N1 LNs and increased 
in the N2 and N3 LNs. CD163+ M2-type macrophages produce interleukin 
(IL)-10, IL-1β, and vascular endothelial growth factor (VEGF), which contribute 
to tumor growth. In the present study, one patient with N2 LNs (stage IIB) 
progressed to the N3 stage associated with erythroderma within 55 months, and 
died of tumor progression and bacterial infection. Another patient (stage IIIA) 
had no progression of the illness in a 46-month follow-up period. 
The presence of many DC-LAMP (CD208)+ DCs with a concomitant decrease of 
DC-SIGN (CD209)+ and scant infiltration of CD163+ M2-type macrophages in 
the outer and paracortex in N1 LNs might be protective for tumor growth. In 
contrast, the increased number of CD163+ M2-type macrophages might be 
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Figure 1. Histopathological features of examined LNs. MF patients: (A-F). 
Control (melanoma) patients: (G, H). Hematoxylin-Eosin stainings (N1: A; N2: C; 
N3: E; Control: G). Immunochemical stainings: S-100 protein (N1: B; N2: D; N3: 
F; Control: H). N1 and N2 revealed the accumulation of S-100 protein+ cells in 
the outer and paracortex areas. Bar indicate 500 μm in length. 
 
Figure 2. Immunofluorescence study of the N1 LNs. (S-100 protein: (A-F); 
CD1a: G; Langerin: H; DC-LAMP: I; DC-SIGN: J; CD68: K; CD14: L). (Overlay 
S-100 protein/CD1a: M; S-100 protein/Langerin: N; S-100 protein/DC-LAMP: O; 
S-100 protein/DC-SIGN: P; S-100 protein/CD68: Q; S-100 protein/CD14: R). 
CD68+ cells are distinct from S-100 protein+ cells. Most CD14+ cells are distinct 
from S-100 protein+ cells. Langerin+, CD1a+, DC-SIGN+ and DC-LAMP+ cells 
co-expressed S-100 protein. 
 
Figure 3. Localization of DC subsets in the LNs. MF: (A, C, E, G); Control: (B, D, 
F, H); DC-LAMP: (A, B); DC-SIGN: (C, D); CD1a: (E, F); Langerin: (G, H). 
Compared with the control, DC-LAMP (CD208)+ cells are significantly increased 
in density in the outer and paracortex areas (T-cell zone) of the N1 and N2, 
where a small number of DC-SIGN (CD209)+ cells are present. Bar indicate 200 
μm in length. 
 
Figure 4. The proportion of DC-LAMP+ cells in the N1 and N2 LNs are 
significantly increased in outer and paracortex areas of MF, as compared with 
those in control. The median proportion: N1: 77.0% vs. 39.5%, **p=0.0009, and 
N2: 85.5% vs. 39.5%, **p=0.0084, respectively.  
The Mann-Whitney U test, with a significance level of ** p<0.01 and * p<0.05. 
 
Figure 5. The proportion of DC-SIGN+ cells is significantly decreased in the MF 
compared to that of the control group (14.5% vs. 36.6%, p=0.0481, respectively). 
No significant difference is observed in the proportion of CD1a+ or Langerin 
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(CD207)+ cells  between the MF and control groups (CD1a+: 34.5% vs. 40%, 
p=0.938; Langerin (CD207)+: 13.5% and 13.5%, p=0.969, respectively).  
The Mann-Whitney U test, with a significance level of ** p<0.01 and * p<0.05 
 
Figure 6. CD163+ cells in the LNs of MF. N1: A; N2: B; N3: C; magnifying image 
of A: D; magnifying image of B: E; magnifying image of C: F. The number of 
CD163+ cells is increased in the N2 and N3. (4.8±2.6/HPF and 2.0±0.8/HPF, 
respectively). Bar indicate 200 μm in length. 
HPF: high power field 
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